Lutetium-177 oxodotreotide - Jiangsu HengRui Medicine
Alternative Names: Lutetium (177Lu) Oxodotreotide Injection - Jiangsu HengRui MedicineLatest Information Update: 24 Aug 2023
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Antineoplastics; Drug conjugates; Peptides; Radioisotopes; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters; Somatostatin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Neuroendocrine tumours
Most Recent Events
- 06 Jul 2023 Phase-III clinical trials in Neuroendocrine tumours (Late-stage disease, Inoperable/Unresectable, Metastatic disease) in China (Parenteral) (NCT05884255)
- 01 Jun 2023 Jiangsu HengRui Medicine plans a phase III trial for Neuroendocrine tumours (Late-stage disease, Inoperable/Unresectable, Metastatic disease) (Parenteral) in June 2023 (NCT05884255)
- 01 Jun 2023 Preclinical trials in Neuroendocrine tumours in China (Parenteral) prior to June 2023